Last updated: February 20, 2026
What is NDC 55494-0580?
NDC 55494-0580 corresponds to Xywav, a liquid formulation of calcium, magnesium, sodium, and potassium oxybates used to treat conditions like narcolepsy and idiopathic hypersomnia. Developed by Jazz Pharmaceuticals, Xywav received FDA approval in July 2020. The drug stands as a successor to Sodium Oxybate (Xyrem), with a lower sodium content, positioning it within scheduled treatments for narcolepsy.
Market Size and Growth Dynamics
Current Market Landscape
- The global narcolepsy therapeutics market was valued at approximately $800 million in 2022 and is projected to reach $1.2 billion by 2028 at a CAGR of 6.1% (Fortune Business Insights, 2023).
- The U.S. accounts for around 70% of this market, with an estimated $560 million in 2022.
Key Drivers
- Increasing diagnosis rates for narcolepsy and hypersomnia.
- Growing acceptance of oxybate therapies due to proven efficacy.
- Expanded indications, including off-label uses for treatment-resistant conditions.
Market Segments
| Segment |
Share (2022) |
Projected CAGR (2023-2028) |
| Narcolepsy treatment |
65% |
6.2% |
| Idiopathic hypersomnia |
20% |
6.3% |
| Off-label uses |
15% |
5.8% |
Competitive Landscape
- Xywav and Xyrem (sodium oxybate) dominate the market.
- Competing therapies include modafinil, armodafinil, and newer wake-promoting agents.
- Biosimilars or alternative formulations are in early development but lack significant market presence.
Price Trends and Projections
Historical Pricing
- Xywav is priced approximately at $70,000 per year per patient (February 2023 estimate).
- Xyrem averages $60,000 annually, but with the advantage of longstanding market presence.
Price Dynamics
- The initial launch price of Xywav was set at a premium relative to Xyrem, reflecting lower sodium content and improved tolerability.
- The high cost is partly driven by the drug's controlled substance status, manufacturing complexity, and limited competition.
Price Projections (2023-2028)
| Year |
Estimated Price Per Patient |
Rationale |
| 2023 |
$70,000 |
Current pricing, stable demand |
| 2024 |
$72,000 |
Slight inflation, increased demand |
| 2025 |
$74,000 |
Potential price negotiations or insurance pressure |
| 2026 |
$75,500 |
Market maturation, new entrants unlikely early |
| 2027 |
$77,000 |
Slight price inflation with steady demand |
| 2028 |
$78,500 |
Inflation adjustments, potential regulatory impacts |
Prices assume no significant regulatory hikes or declines due to generic entry.
Revenue Projections
Assuming a market penetration of 10,000 patients in the U.S. by 2028, revenue from Xywav could reach:
| Year |
Estimated Revenue (USD) |
Market Penetration Assumption |
| 2023 |
$700 million |
10,000 patients at $70,000 |
| 2028 |
$785 million |
10,000 patients at $78,500 |
Regulatory and Pricing Pressures
- The DEA schedules oxybates as controlled substances, affecting supply chain and pricing policies.
- Potential for price negotiations through insurance and Medicare coverage episodes.
- Patent expirations are unlikely before 2030, preserving market exclusivity.
Opportunities and Risks
Opportunities
- Expansion into off-label indications like treatment-resistant depression.
- Development of proprietary formulations or delivery mechanisms.
- Increased adoption due to ongoing clinical trials demonstrating benefits.
Risks
- Entry of biosimilar or generic oxybate products.
- Regulatory changes that could impose price caps or reduce reimbursement.
- Supply chain constraints affecting availability and pricing.
Key Takeaways
- The narcolepsy market is expanding at a CAGR of approx. 6.1%, with Xywav maintaining a premium price due to its lower sodium formulation.
- Price per patient is projected to rise modestly, reaching about $78,500 by 2028.
- Total revenues could approach $785 million annually, assuming sustained market penetration.
- Competitive threats from biosimilars or off-label alternatives could impact pricing and market share.
- Regulatory and insurance negotiations will influence pricing dynamics over the forecast period.
FAQs
Q1: Will the price of Xywav decline due to generic entry?
A: Generic oxybate products are not yet available; patent protection still applies, delaying generic entry until approximately 2030.
Q2: How does Xywav compare to Xyrem in market adoption?
A: Xywav's lower sodium content and improved side effect profile favor its adoption, but Xyrem retains a significant market share due to established prescribing habits.
Q3: What factors could accelerate price growth?
A3: Increased demand, regulatory approvals for new indications, or limited competition could push prices higher.
Q4: How does insurance coverage impact pricing?
A: Insurance negotiations may lead to rebates, formulary placements, or tiered pricing, affecting net revenue projections.
Q5: Are there emerging competitors?
A: Currently, no direct biosimilars or competitors exist, but pipeline products could impact the landscape within the next 5-7 years.
References
- Fortune Business Insights. (2023). Narcolepsy Market Size, Share & Industry Analysis. Retrieved from https://www.fortunebusinessinsights.com
- FDA. (2020). Xywav approval announcement. [FDA.gov]
- Medicare.gov. (2023). Drug price and reimbursement policies for controlled substances.
- IQVIA. (2023). U.S. Prescription Drug Market Data.
- Jazz Pharmaceuticals. (2022). Xywav prescribing information.
